


## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1128	wallach.in. or ramakrishnan.in. or "shmushkovich.in"	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:05
L2	91	l1 and (nik or (NF-kappa B-inducing kinase))	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08
L3	200	IL-2 near6 (nik or (NF-kappa B-inducing kinase))	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08
L4	2	l2 and l3	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08



A service of the National Library of Medicine  
and the National Institutes of Health



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

About Entrez

All: 95 Review: 95

Text Version

Selected: 8

Items 81 - 95 of 95

Previous  of 5

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ **81:** Shand N, Richardson B. [Related Articles, Links](#)



Sandimmun (cyclosporin A): mode of action and clinical results in rheumatoid arthritis.

Scand J Rheumatol Suppl. 1988;76:265-78. Review.

PMID: 3075082 [PubMed - indexed for MEDLINE]

☐ **82:** Ostensen M, Forre O. [Related Articles, Links](#)



Modulation of human natural killer cell function by cytokines and rheumatic disease.

Scand J Rheumatol Suppl. 1988;76:183-8. Review.

PMID: 3075075 [PubMed - indexed for MEDLINE]

☐ **83:** Kitas GD, Salmon M, Allan IM, Bacon PA. [Related Articles, Links](#)



The T cell system in rheumatoid arthritis: activated or defective?

Scand J Rheumatol Suppl. 1988;76:161-73. Review.

PMID: 3075073 [PubMed - indexed for MEDLINE]

☐ **84:** Forre O, Waalen K, Natvig JB, Kjeldsen-Kragh J. [Related Articles, Links](#)



Evidence for activation of rheumatoid synovial T lymphocytes--development of rheumatoid T cell clones.

Scand J Rheumatol Suppl. 1988;76:153-60. Review.

PMID: 3075072 [PubMed - indexed for MEDLINE]

☐ **85:** Kolarz G. [Related Articles, Links](#)










Pathogenesis of rheumatoid arthritis.


Acta Med Austriaca. 1988;15(5):128-30. Review.


PMID: 2464266 [PubMed - indexed for MEDLINE]


☐ **86:** Kucharz EJ. [Related Articles, Links](#)

[Plasma inhibitors of interleukin 2 in normal conditions and in


-  pathological states]  
Wiad Lek. 1987 Aug 15;40(16):1111-5. Review. Polish. No abstract available.  
PMID: 3326287 [PubMed - indexed for MEDLINE]
- ▢ 87: Arenzana-Seisdedos F, Teyton L, Virelizier JL. Related Articles, Links
-  Immunoregulatory mediators in the pathogenesis of rheumatoid arthritis.  
Scand J Rheumatol Suppl. 1987;66:13-7. Review.  
PMID: 3131870 [PubMed - indexed for MEDLINE]
- ▢ 88: Emery P, Williamson DJ, Mackay IR. Related Articles, Links
-  Role of cytokines in rheumatological inflammation.  
Concepts Immunopathol. 1987;4:171-99. Review. No abstract available.  
PMID: 2439208 [PubMed - indexed for MEDLINE]
- ▢ 89: Sibbitt WL Jr, Bankhurst AD. Related Articles, Links
-  Natural killer cells in connective tissue disorders.  
Clin Rheum Dis. 1985 Dec;11(3):507-21. Review.  
PMID: 3907953 [PubMed - indexed for MEDLINE]
- ▢ 90: Talal N. Related Articles, Links
-  Interleukins, interferon and rheumatic disease.  
Clin Rheum Dis. 1985 Dec;11(3):633-44. Review. No abstract available.  
PMID: 2416506 [PubMed - indexed for MEDLINE]
- ▢ 91: Stecher VJ, Carlson JA, Connolly KM, Bailey DM. Related Articles, Links
-  Disease-modifying antirheumatic drugs.  
Med Res Rev. 1985 Jul-Sep;5(3):371-90. Review. No abstract available.  
PMID: 3894835 [PubMed - indexed for MEDLINE]
- ▢ 92: Pichler WJ, Emmendorffer A, Peter HH, Deicher HR, Fontana A, de Weck AL. Related Articles, Links
-  [Analysis of T-cell subpopulations. Pathophysiological concept and significance for clinical medicine]  
Schweiz Med Wochenschr. 1985 Apr 20;115(16):534-50. Review. German.  
PMID: 3159084 [PubMed - indexed for MEDLINE]
- ▢ 93: Boumpas DT, Tsokos GC. Related Articles, Links

 Pathophysiologic aspects of lymphokines.  
Clin Immunol Rev. 1985;4(2):201-40. Review.  
PMID: 2417771 [PubMed - indexed for MEDLINE]

 **94:** [Alarcon-Segovia D.](#) [Related Articles, Links](#)

 Mixed connective tissue disease: a disorder of immune regulation.  
Semin Arthritis Rheum. 1983 Aug;13(1 Suppl 1):114-20. Review. No abstract available.  
PMID: 6226095 [PubMed - indexed for MEDLINE]

 **95:** [Mizel SB.](#) [Related Articles, Links](#)

 Biochemical and biological characterization of lymphocyte-activating factor (LAF) produced by the murine macrophage cell line, P388D.  
Ann N.Y Acad Sci. 1979;332:539-49. Review. No abstract available.  
PMID: 231409 [PubMed - indexed for MEDLINE]


Items 81 - 95 of 95 [Previous](#) [Page](#)  of 5  
Display  Show  Sort by  Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 19 2007 07:18:03



A service of the National Library of Medicine  
and the National Institutes of Health



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

About Entrez

All: 5 Review: 1

Text Version

Items 1 - 5 of 5

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Sanchez-Valdepenas C, Martin AG, [Related Articles, Links](#)  
Ramakrishnan P, Wallach D, Fresno M.

NF-kappaB-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity.  
J Immunol. 2006 Apr 15;176(8):4666-74.  
PMID: 16585559 [PubMed - indexed for MEDLINE]

☐ 2: Lu LF, Gondek DC, Scott ZA, Noelle RJ. [Related Articles, Links](#)

NF kappa B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation.  
J Immunol. 2005 Aug 1;175(3):1651-7.  
PMID: 16034105 [PubMed - indexed for MEDLINE]


☐ 3: Matsumoto M, Yamada T, Yoshinaga SK, [Related Articles, Links](#)  
Boone T, Horan T, Fujita S, Li Y, Mitani T.


Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway.  
J Immunol. 2002 Aug 1;169(3):1151-8.  
PMID: 12133934 [PubMed - indexed for MEDLINE]

☐ 4: Yamada T, Mitani T, Yorita K, Uchida D, [Related Articles, Links](#)  
Matsushima A, Iwamasa K, Fujita S,  
Matsumoto M.

Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase.  
J Immunol. 2000 Jul 15;165(2):804-12.  
PMID: 10878354 [PubMed - indexed for MEDLINE]

☐ 5: O'Neill LA, Greene C. [Related Articles, Links](#)

-  Signal transduction pathways activated by the IL-1 receptor family:  
ancient signaling machinery in mammals, insects, and plants.  
J Leukoc Biol. 1998 Jun;63(6):650-7. Review.  
PMID: 9620655 [PubMed - indexed for MEDLINE]

Display   Show   Sort by  Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 19 2007 07:18:03

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	"5854003".pn.	US-PGPUB; USPAT	OR	OFF	2007/03/22 20:32
L2	3	(NF-kappa B-inducing kinase or NIK) near8 (IL-2 or IL2)	US-PGPUB; USPAT	ADJ	OFF	2007/03/22 20:46

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*  
\* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPlus pre-1967 chemical substance index entries enhanced
			with preparation role
NEWS	4	DEC 18	CA/CAPlus patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPlus accession number crossover limit increased
			to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPlus enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPlus Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPlus updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPlus enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in
			multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000



to 300,000 in multiple databases

NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display  
format

NEWS 25 MAR 16 CASREACT coverage extended

NEWS 26 MAR 20 MARPAT now updated daily

NEWS 27 MAR 22 LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation  
of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 20:52:45 ON 22 MAR 2007

=> File Medline EMBASE Biosis Caplus  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 20:53:02 ON 22 MAR 2007

FILE 'EMBASE' ENTERED AT 20:53:02 ON 22 MAR 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 20:53:02 ON 22 MAR 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 20:53:02 ON 22 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (NF-kappa B-inducing kinase or NIK) (8A) (IL-2 or IL2)  
L1 10 (NF-KAPPA B-INDUCING KINASE OR NIK) (8A) (IL-2 OR IL2)

=> duplicate  
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove  
ENTER L# LIST OR (END):11  
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L1  
L2 4 DUPLICATE REMOVE L1 (6 DUPLICATES REMOVED)

=> d l2 1-4 bib ab

L2 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1  
AN 2006187607 MEDLINE  
DN PubMed ID: 16585559  
TI NF-kappaB-inducing kinase is involved in the activation of the  
CD28 responsive element through phosphorylation of c-Rel and  
regulation of its transactivating activity.  
AU Sanchez-Valdepenas Carmen; Martin Angel G; Ramakrishnan  
Parameswaran;  
Wallach David; Fresno Manuel  
CS Centro de Biologia Molecular, Consejo Superior de Investigaciones  
Cientificas, Universidad Autonoma de Madrid, Madrid, Spain.  
SO Journal of immunology (Baltimore, Md. : 1950), (2006 Apr 15)  
Vol. 176, No. 8, pp. 4666-74.  
Journal code: 2985117R. ISSN: 0022-1767.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200605  
ED Entered STN: 5 Apr 2006  
Last Updated on STN: 17 May 2006  
Entered Medline: 16 May 2006  
AB Previous evidence suggested that NF-kappaB-inducing kinase (NIK)  
might regulate IL-2 synthesis. However, the molecular  
mechanism is not understood. In this study, we show that NIK is  
involved in CD3 plus CD28 activation of IL-2  
transcription. Splenic T cells from aly/aly mice (that have a  
defective NIK protein) have a severe impairment in IL-2  
and GM-CSF but not TNF secretion in response to CD3/CD28. This  
effect takes place at the transcriptional level as overexpression of  
alyNIK inhibits IL-2 promoter transcription. NIK activates the CD28  
responsive element (CD28RE) of the IL-2 promoter and  
strongly synergizes with c-Rel in this activity. We found that  
NIK

interacts with the N-terminal domain of c-Rel, mapping this interaction to aa 771-947 of NIK. Moreover, NIK phosphorylates the c-Rel C-terminal transactivation domain (TAD) and induces Gal4-c-Rel-transactivating activity. Anti-CD28 activated Gal4-c-Rel transactivation activity, and this effect was inhibited by a NIK-defective mutant. Deletion studies mapped the region of c-Rel responsive to NIK in aa 456-540. Mutation of several serines, including Ser471, in the TAD of c-Rel abrogated the NIK-enhancing activity of its transactivating activity. Interestingly, a Jurkat mutant cell line that expresses one of the mutations of c-Rel (Ser471Asn) has a severe defect in IL-2 and CD28RE-dependent transcription in response to CD3/CD28 or to NIK. Our results support that NIK may be controlling CD28RE-dependent transcription and T cell activation by modulating c-Rel phosphorylation of the TAD. This leads to more efficient transactivation of genes which are dependent on CD28RE sites where c-Rel binds such as the IL-2 promoter.

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:837297 CAPLUS  
 DN 139:312400  
 TI Modulation of NIK with IL-2 common  $\gamma$  chain and therapeutic uses thereof  
 IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia  
 PA Yeda Research and Development Co.Ltd, Israel  
 SO PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.
DATE	-----	----	-----	-----
-----				

PI	WO 2003087380	A1	20031023	WO 2003-IL317
20030415				
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,			
CH, CN,	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,			
GE, GH,				

LK, LR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 NZ, OM, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 TR, TT, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN,  
 RW: TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 AZ, BY, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 EE, ES, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 SK, TR, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,  
 TD, TG BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,

CA 2482387 A1 20031023 CA 2003-2482387  
 20030415

AU 2003226607 A1 20031027 AU 2003-226607  
 20030415

EP 1499729 A1 20050126 EP 2003-746399  
 20030415

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
 MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,  
 SK

JP 2005530491 T 20051013 JP 2003-584319  
 20030415

US 2005272633 A1 20051208 US 2005-511314  
 20050517

PRAI IL 2002-149217 A 20020418  
 IL 2002-152183 A 20021008  
 WO 2003-IL317 W 20030415

AB This invention relates to the use of NIK and related mols. for  
 the  
 modulation of signal activities controlled by cytokines, and  
 some new such  
 mols. In addition the invention relates to the use of a DNA  
 encoding NIK, or  
 its antisense , NIK specific antibodies, a small mol. obtainable  
 by  
 screening products of combinatorial chemical in a luciferase  
 system, for  
 modulating the interaction between IL-2 common gamma  
 chain (cyc) and NIK. The present invention also relates  
 to the use of NIK or a mutein, variant, fusion protein,  
 functional derivative,  
 circularly permuted derivative or fragment thereof, in the  
 manufacture of a  
 medicament for the treatment of a disease, wherein a cytokine  
 stimulating  
 signalling through the IL-2 cyc is involved in the pathogenesis  
 of

the disease.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:837291 CAPLUS

DN 139:328743

TI Modulating interaction of IL-2 with NIK by  
derivatives of the IL-2 common gamma chain, and  
therapeutic uses thereof

IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia

PA Yeda Research and Development Co. Ltd., Israel

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE			
-----	----	-----	-----
-----			
PI WO 2003087374	A1	20031023	WO 2003-IL316
20030415			
WO 2003087374	A9	20050127	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,			
CH, CN,			
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,			
GE, GH,			
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			
LK, LR,			
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,			
NZ, OM,			
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN,			
TR, TT,			
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			
AZ, BY,			
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			
EE, ES,			
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,			
SK, TR,			
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,			
TD, TG			
CA 2482718	A1	20031023	CA 2003-2482718
20030415			
AU 2003222415	A1	20031027	AU 2003-222415
20030415			
EP 1499724	A1	20050126	EP 2003-717504
20030415			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,			
MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,

SK

JP 2005525113 T 20050825 JP 2003-584315  
20030415

US 2005287144 A1 20051229 US 2005-511722  
20050622

PRAI IL 2002-149217 A 20020418  
IL 2002-152183 A 20021008  
WO 2003-IL316 W 20030415

AB This invention relates to the use of IL-2 common gamma chain  
(cyc)

and related mols. for the modulation of signal activities  
controlled by

cytokines, and therapeutic uses thereof. Specifically, the  
invention

relates to the use of IL-2 cyc or a mutein, variant, fusion  
protein,

the intracellular domain of cyc (ICDcyc), 1-357, 1-341  
functional derivative, circularly permuted derivative or  
fragment thereof for

modulating the interaction between cyc and NIK. In addition the  
invention relates to the use of a DNA encoding cyc or derivs.,

a DNA

encoding the antisense of cyc, an antibody specific to cyc, or  
a small mol. obtainable by screening products of combinatory

chemical in a

luciferase system, for modulating the interaction between IL-  
2 common gamma chain (cyc) and NIK. In another

aspect, the invention provides the use of cyc or derivs. in the  
manufacture of a medicament for treatment of a disease, wherein

NIK activity is

involved in the pathogenesis of the disease.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 2

AN 2002385095 MEDLINE

DN PubMed ID: 12133934

TI Essential role of NF-kappa B-inducing kinase in T cell  
activation through

the TCR/CD3 pathway.

AU Matsumoto Mitsuru; Yamada Takuji; Yoshinaga Steven K; Boone Tom;  
Horan

Tom; Fujita Shigeru; Li Yi; Mitani Tasuku

CS Division of Molecular Immunology, Institute for Enzyme Research,  
University of Tokushima, Tokushima, Japan..

mitsuru@ier.tokushima-u.ac.jp

SO Journal of immunology (Baltimore, Md. : 1950), (2002 Aug 1) Vol.  
169, No.

3, pp. 1151-8.

Journal code: 2985117R. ISSN: 0022-1767.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200208  
 ED Entered STN: 23 Jul 2002  
 Last Updated on STN: 30 Aug 2002  
 Entered Medline: 13 Aug 2002  
 AB NF-kappa B-inducing kinase (NIK) is involved in lymphoid  
 organogenesis in  
 mice through lymphotoxin-beta receptor signaling. To clarify  
 the roles of  
 NIK in T cell activation through TCR/CD3 and costimulation  
 pathways, we  
 have studied the function of T cells from aly mice, a strain  
 with mutant  
 NIK. NIK mutant T cells showed impaired proliferation and  
 IL-2 production in response to anti-CD3 stimulation, and  
 these effects were caused by impaired NF-kappa B activity in  
 both mature  
 and immature T cells; the impaired NF-kappa B activity in mature  
 T cells  
 was also associated with the failure of maintenance of activated  
 NF-kappa  
 B. In contrast, responses to costimulatory signals were largely  
 retained  
 in aly mice, suggesting that NIK is not uniquely coupled to the  
 costimulatory pathways. When NIK mutant T cells were stimulated  
 in the  
 presence of a protein kinase C (PKC) inhibitor, proliferative  
 responses  
 were abrogated more severely than in control mice, suggesting  
 that both  
 NIK and PKC control T cell activation in a cooperative manner.  
 We also  
 demonstrated that NIK and PKC are involved in distinct NF-kappa B  
 activation pathways downstream of TCR/CD3. These results  
 suggest critical  
 roles for NIK in setting the threshold for T cell activation,  
 and partly  
 account for the immunodeficiency in aly mice.